T HYROID HORMONE SYNTHESIS is tightly regulated by a negative feedback system involving the hypothalamus, pituitary, and thyroid gland. In most forms of hyperthyroidism, elevation of T 3 and T 4 represses secretion of TSH by the pituitary gland. However, in patients with TSH-secreting pituitary tumors (TSHomas), this negative feedback is disrupted, as TSHomas overproduce TSH in the face of elevated serum T 3 and T 4 levels (1, 2). Furthermore, TSH secretion cannot be stimulated by TRH. These patients typically have physical signs and symptoms of thyroid hormone excess. Additionally, TSHomas present almost invariably as macroadenomas and can cause visual and vascular complications. The mechanism for this loss of negative regulation of TSH secretion by thyroid hormone in TSHomas is not known but may involve a defect in signaling via thyroid hormone receptors (TRs).
TRs are members of a family of nuclear hormone receptors that include the steroid hormone, vitamin D, and retinoic acid receptors (3, 4) . These receptors have a variable amino terminus, a central DNA-binding domain, and a carboxy-terminal ligand-binding domain. TRs bind to their thyroid hormone response elements, usually located in the promoter regions of target genes, and regulate transcription by interacting with coactivators and corepressors (5) . In positively regulated target genes, coactivators mediate hormone-induced activation, while corepressors, nuclear receptor corepressor (NCoR) and silencing mediator of retinoic acid and thyroid hormone receptor (SMRT), mediate transcriptional silencing. In negatively regulated target genes, which are not as well characterized, corepressors activate the glycoprotein hormone ␣-subunit and TSH␤ genes, whereas coactivators such as steroid receptor coactivator-1 (SRC-1), glucocorticoid receptor interacting protein 1, thyroid receptor activator molecule 1, and activator of thyroid and retinoic acid receptors enhance the T 3 -dependent negative regulation of glycoprotein hormone ␣-subunit gene (6, 7) .
There are two distinct TR genes, TR␣ and TR␤. The TR␣ gene generates two proteins, TR␣1 and a car-boxy-terminal splice variant, c-erbA␣2, that does not bind thyroid hormone. The TR␤ gene generates two isoforms, TR␤1 and TR␤2, via promoter choice (8) . TR␤1 and TR␤2 proteins have identical DNA-and ligand-binding domains, but differ at their amino termini. Although TR␣1, TR␤1, and c-erbA␣2 have widespread expression, TR␤2 has tissue-selective expression in the anterior pituitary gland, hypothalamus, and developing brain (9, 10) . Recently, TR␤2-selective knockout mice have been generated, which manifest elevated serum TSH and thyroid hormone levels (11) . This finding suggests that TR␤2 may be the critical TR isoform that negatively regulates TSH secretion.
Patients with the inherited syndrome of resistance to thyroid hormone (RTH) also have elevated serum T 3 and T 4 concentrations and normal or elevated TSH level (12) (13) (14) . These patients generally have point mutations in one of the alleles of the TR␤ gene that results in a mutant TR that cannot bind T 3 or regulate transcription but can nonetheless bind to thyroid hormone response elements of target genes. The dominant negative activity of the mutant TR␤ on wild-type TR reduces thyroid hormone suppression of the two genes that generate TSH subunits: glycoprotein hormone ␣-subunit and TSH␤ (15, 16) . Given the precedence for TR␤ mutations in RTH patients, we performed mutational analysis of TR␤ isolated from a surgically resected TSHoma. Surprisingly, we detected a splice variant of TR␤ mRNA that translates into an abnormal TR␤2 protein that is unable to bind T 3 . This abnormal TR␤2 was transcriptionally inactive and disrupted the negative regulation of TSH by T 3 in cotransfection studies. These findings suggest that a novel, posttranscriptional mechanism caused central thyroid hormone resistance in this patient with a TSHoma. Similar posttranscriptional mechanisms may explain other hormone-resistant states or tumors in which no hormone receptor mutations can be detected from genomic DNA.
RESULTS

Clinical Studies
A 79-yr-old Caucasian female presented at NIH with goiter and palpitations due to hyperthyroidism. The patient had a serum TSH concentration of 10.5 U/ml (normal, 0.43-4.60), free T 4 concentration of 7.4 ng/dl (normal, 0.9-1.6), and glycoprotein hormone ␣-subunit concentration of 34.1 g/liter (normal, Ͻ5). Serum GH and PRL levels were normal. A magnetic resonance image of pituitary revealed an 18-mm pituitary adenoma with extension into the left cavernous sinus. Transsphenoidal surgery was performed, and immunohistochemical analysis of the tumor showed strongly positive staining for TSH and glycoprotein hormone ␣-subunit, as well as staining for both GH and PRL. Postoperatively, the patient's serum TSH decreased to 3.1 U/ml. However, the tumor could not be completely removed due to dural invasion, and the patient was started on octreotide therapy. The patient's symptoms abated and her thyroid function tests normalized. A TRH stimulation test showed normal TSH secretory response (data not shown). A T 3 suppression test performed 4 yr after surgery (Fig. 1) failed to suppress the patient's serum TSH to less than 10% of the baseline, suggesting that at least part of the patient's TSH secretion was due to residual tumor (1) . Annual pituitary magnetic resonance imagings have shown a persistent 7-mm residual adenoma with no further growth. The patient's clinical status has remained unchanged.
Finding of TR␤2 mRNA Splice Variant from a TSHoma
RNA from the patient's TSHoma and pooled normal pituitaries were used to amplify full-length TR␤1, TR␤2, and an internal control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA by RT-PCR. Similar amounts of GAPDH mRNA were detected in the samples, suggesting that similar amounts of RNA were analyzed from the TSHoma and the pooled normal pituitaries ( Fig. 2A, lanes 5 and 6) . Additionally, similar amounts of TR␤1 mRNA were measured in the TSHoma and pooled normal pituitaries ( Fig. 2A, lanes  1 and 2) . Surprisingly, a short variant TR␤2 mRNA (TR␤2spl) was the major amplified product from the TSHoma, as only a small amount of amplified wildtype TR␤2 product was observed ( Fig. 2A, lane 4) . In T 3 (300 g) was administered orally to the patient, and serum samples were obtained just before, and 48 h after, T 3 administration for measurement of serum TSH. Normal basal serum TSH ranges from 0.43 to 4.60 U/liter. Normal controls suppress to less than 10% of the baseline 48 h after T 3 administration. Shaded areas represent normal ranges for baseline serum TSH and expected ranges for T 3 -suppressed serum TSH 48 h after T 3 administration, respectively. contrast, only the wild-type TR␤2 product was amplified from the pooled normal pituitary RNA (Fig. 2A,  lane 3 ). TR␤2spl mRNA was detected only in the TSHoma RNA when RT-PCR was performed using TR␤2 exon 6 primers (data not shown). Taken together, these findings suggested that TR␤2spl mRNA was specific for the TSHoma and contained a deletion within exon 6. Furthermore, since the primers used for amplification detected full-length TR␤2 cDNA, they enabled measurement of the relative expression of both wild-type TR␤2 and TR␤2spl mRNA within the same PCR reaction. These semiquantitative RT-PCR results showed that there is much higher expression of TR␤2spl mRNA than wild-type TR␤2 mRNA in the TSHoma, although the total amount of TR␤2 mRNA is not significantly different than TR␤2mRNA from the pooled normal pituitaries (Fig. 2B) . Similar findings were observed in three repeat experiments. The intensities of the bands in Fig. 2A , lanes 3 and 4, corrected for GADPH mRNA expression, are shown in Fig. 2B . The RT-PCR products then were sequenced, and the TR␤2spl mRNA was found to have a 135 base in-frame deletion in exon 6 (Fig. 3 ). This deleted region was identical in TR␤1 and TR␤2 and encoded a part of the ligand-binding domain. Additionally, TR␤2spl protein had a newly created isoleucine in place of the deleted 46 amino acids in the ligand-binding domain (Fig. 3) . PCR was performed using genomic DNA from 
Analysis of Splice Sites
Examination of both 5Ј-and 3Ј-sequences flanking the junction site of the deletion of TR␤2spl mRNA showed near-consensus splicing sequences that were located within exon 6 of wild-type TR␤2 (Fig. 4 A) . These sequences conformed to several rules that are important for efficient splicing (17, 18) . Most splice junctions are bordered by GT/AG at the 5Ј-and 3Ј-ends of the spliced sequences, as was the case for TR␤2spl mRNA. Additionally, there are consensus sequences for the 5Ј-splice site (ss), 3Ј-ss, and branch sequence, which are located 20 to 50 bases upstream of the 3Ј-ss. TR␤2 mRNA had near-consensus 5Ј-and 3Ј-splice sequences, as well as a consensus branch sequence within exon 6 (Fig. 4B) . Using an internal coding exon predicting program, Michael Zhang's Exon Finder (19) , the 5Ј-ss and 3Ј-ss used by TR␤2spl had scores indicating their high potential for alternative splicing (AAAGTGAGA, 5Ј-ss score ϭ 46.77; TGGAT-GACACTGAAGTA, 3Ј-ss score ϭ75.47), although their scores were slightly lower than those of the wild-type TR␤ ss (CAGGTGAGT, 5Ј-ss score ϭ 49.93; ACTG-GTTCTTTTCAGCT, 3Ј-ss score ϭ83.75).
Aberrant alternative splicing theoretically could be due to somatic mutations in the genomic DNA of the TSHoma, which, in turn, might generate a new cryptic splice site or create an unfavorable splice sequence in the intron/exon junctions of exon 6. However, sequencing of the PCR products from genomic DNA of the TSHoma showed no mutation in exon 6 and or in the flanking intronic sequences (data not shown). These findings demonstrate that TR␤2spl was created by aberrant splicing via latent splice sites that existed within exon 6 of wild-type TR␤2 mRNA.
Functional Properties of TR␤2 Splice Variant
Most mutations identified in patients with RTH are located in three clusters of the ligand-binding domain of TR␤ (cluster 1: TR␤1 234-282, cluster 2: TR␤1 310-383, cluster 3: TR␤1 429-460) (20) . The deletion of TR␤2spl is located within cluster 2 of the ligand-binding domain of TR␤2. Since most RTH mutants reduced binding to T 3 , the T 3 -binding activity of TR␤2spl was measured and compared with the T 3 -binding activities of wild-type TR␤2 and TR␤2G360R (TR␤2Mf), a cluster 2 mutant from a patient with RTH previously shown to have minimal T 3 binding (20a). As expected from the location of the deletion in the ligand-binding domain, both TR␤2spl and TR␤2Mf showed minimal T 3 binding (Fig. 5) . We then examined the functional activity of the wild-type TR␤2 and TR␤2spl on the regulation of the genes encoding the two subunits of TSH: glycoprotein hormone ␣-subunit and TSH␤. It has been previously shown that wild-type TR can cause T 3 independent activation and T 3 -dependent negative regulation of transcription for these two genes (6, 15) . As shown in Fig. 6 , TR␤2spl lost both T 3 independent activation and T 3 -dependent negative regulation on glycoprotein hormone ␣-subunit and TSH␤ genes. In the presence of T 3 , TR␤2spl also showed higher transcriptional activity of the glycoprotein hormone ␣-subunit and TSH␤ genes than wild-type TR␤2, consistent with the clinical observation of nonsuppressible TSH in the face of elevated T 3 observed in the patient (Fig. 1) . Cotransfection of the wild-type TR␤2 with TR␤2spl, as well as TR␤2Mf, resulted in diminished T 3 -dependent negative regulation of both glycoprotein hormone ␣-subunit and TSH␤ genes (Fig. 7) . These results show that both TR␤2spl and TR␤2Mf have strong dominant negative activity against the wild-type TR␤2 on the transcription of glycoprotein hormone ␣-subunit and TSH␤ genes.
To study the interaction between TR␤2spl and transcriptional cofactors, the LexA yeast two-hybrid system was used. cDNAs of the ligand-binding domains of wild-type TR␤ and TR␤2spl were subcloned into LexA expression vector, and coactivators, SRC-1 and transcription intermediary factor 2 (TIF2), and corepressors (NCoR and SMRT) were subcloned into B42AD expression vector. As expected, the ligand-binding domain of wild-type TR␤ interacted with both SRC-1 and TIF2 in the presence of ligand and interacted with both NCoR and SMRT in the absence of ligand (Table 1 ). In contrast, the ligand-binding domain of TR␤2spl did not interact with any of these cofactors either in the presence or absence of ligand. 
DISCUSSION
We have found a novel alternatively spliced variant of thyroid hormone receptor, TR␤2spl, from a TSHoma. This is also the first example of abnormal TR in TSHomas. TR␤2spl lacked T 3 -binding activity and was unable to mediate T 3 -dependent negative regulation of glycoprotein ␣-subunit and TSH␤ genes. Furthermore, TR␤2spl showed dominant negative activity, as it blocked T 3 -dependent regulation of both these genes by wild-type TR␤2. These findings strongly implicate TR␤2spl in the defective negative regulation of TSH secretion exhibited by the tumor. This dysregulation in TSH secretion is similar to that observed in patients with RTH who have germline mutations in one of their TR␤ alleles (12) . Additionally, transgenic mice that overexpress dominant negative mutant TR␤s in the pituitary have similar defects in the negative regulation of TSH (21) (22) (23) . In this connection, we recently examined TR␤ in five other TSHomas. Although we did not find another example of aberrant alternative splicing of TRs, we identified a somatic mutation in the ligandbinding domain of TR␤1 in one TSHoma (24). Gittoes et al. (25) recently reported decreased expression of 
. Analysis of Splice Sites
A, Splice sites used for TR␤2spl (red) and normal splice sites (blue and black) are depicted. B, 3Ј-ss, 5Ј-ss, and branch site of TR␤2spl were compared with naturally occurring splice sequences flanking exon 6 of TR␤2, and consensus sequences. The branch site of the deletion of TR␤2spl mRNA is located 48 bases upstream of the 3Ј-ss of the deletion. Underlined nucleotides are absolutely required for splicing. Capitalized nucleotides of the consensus splice sequences are important, whereas lower case nucleotides are less important. Note that TR␤2 exon 6 is the same as TR␤1 exon 9.
TR␣ and TR␤ in two TSHomas; therefore, downregulation of TRs may be an additional mechanism for defective negative regulation of TSH by thyroid hormone. Furthermore, unlike GH-secreting adenomas, which can harbor G protein ␣ chain (Gs␣) mutations that inhibit GTPase activity (26) , no such mutations or TRH receptor mutations have been implicated in the constitutive expression of TSH in TSHomas (27) . Taken together with our study, these findings suggest that defective negative regulation by the TR signaling pathway, rather than overactivity of the TRH signaling pathway, may be operative in some TSHomas.
TR␤2spl had a 46-amino acid deletion replaced by a newly created isoleucine, which maintained the original sequence of the remaining amino acids. The deletion is located in a region of the TR␤ ligand-binding domain where a cluster of mutations has been reported for RTH patients (12) . This region also is known to contribute to the formation of helices 7, 8, and 9 of TR␤, which compose part of the ligand-binding pocket of TR (28) . Thus, the lack of T 3 binding and transcriptional activity, as well as the dominant negative activity observed for TR␤2spl, are fully consistent with a deletion in this important region of the TR␤2 ligandbinding domain. The inability of the ligand-binding domain of TR␤2spl to interact with corepressors and coactivators in the yeast two-hybrid system is consistent with the loss of both T 3 -independent activation and T 3 -dependent negative regulation on glycoprotein hormone ␣-subunit and TSH␤ genes observed in our cotransfection studies. Notably, helices 3, 4, 5, and 6 of TR␤ and helices 3, 5, 6, and 12 of TR␤ have been reported to contact surfaces with corepressors and coactivators, respectively (29-31). Although the deletion of TR␤2spl is not within these areas, tertiary structure changes, presumably due to the large conformational changes caused by the deletion, are likely responsible for the loss of interaction with corepressors. Tertiary structure changes also likely affected T 3 -binding activity and/or coactivator interactions of TR␤2spl.
In our study, only a small amount of wild-type TR␤2 mRNA was detected in the TSHoma, suggesting that TR␤2spl mRNA may have been spliced after wild-type TR␤2 mRNA was generated. Indeed, the 5Ј-ss score and 3Ј-ss score of the TR␤2spl ss were weaker than those of the naturally occurring ss flanking exon 6 of TR␤2. It is interesting that the variant form of TR␤1 mRNA was not observed in the TSHoma, particularly since TR␤1 and TR␤2 have identical sequences coding for the ligand-binding domain. It is possible that TR␤1 and TR␤2 mRNA have different higher order structures or differences in the turnover and/or export rates from the splicesome to account for this difference in splicing of the RNA between the two TR␤ isoforms. Moreover, although TR␤2 and TR␣1 have Wild-type TR␤2, TR␤2spl, or TR␤2Mf was transfected into CV-1 cells. Nuclear extracts were prepared and incubated with 125 I-T 3 as described in Materials and Methods. Bound and free 125 I-T 3 were separated, and the ratio between the bound and total T 3 (B/T) was calculated. The specific T 3 binding was obtained by subtracting the nonspecific binding determined in the incubation mixture containing a 10,000-fold excess of nonlabeled T 3. The value of T 3 -binding activity of the wild-type TR␤2 is expressed as 100%. The data are represented as the mean Ϯ SD of four samples. high homology in the mRNA sequences encoding their respective ligand-binding domains, it is unlikely that TR␣1 has a corresponding splice variant, since TR␣1 has GC/AG instead of GT/AG in the critical sequences that flank the splice junction of TR␤2spl. TR␣ mRNA can undergo alternative splicing to generate mRNA for a non-T 3 binding protein, c-erbA␣-2 (3). However, the location of the ss of TR␤2spl mRNA is more upstream than the 5Ј-ss of c-erbA␣-2 mRNA; therefore, the generation of TR␤2spl mRNA is distinct from this naturally occurring process.
There are several potential mechanisms by which abnormal alternative splicing could generate TR␤2spl mRNA (32, 33) . One possibility is the creation of a new cryptic splice site by a mutation(s) in the genomic DNA. However, this was not observed, as genomic DNA from the patient's TSHoma did not have any mutations in the sequences flanking the splice junction or within the spliced sequence. Another possibility is that a mutation(s) in the natural ss of the flanking introns might create a less favorable splicing site, and thus allow splicing via the intraexonic ss. However, the intraexonic splicing pattern, which maintains portions of exon 6, and the absence of mutations in the naturally occurring ss contained in the intronic sequences immediately flanking exon 6, argue against this possibility. Thus, the most likely explanation for the aberrant splicing is increased activity of splicing factors in the TSHoma. The basis for this phenomenon could be a mutation in a splicing factor(s), or increased splicing activity as a consequence of overexpression or altered function (perhaps by phosphorylation or other regulatory events) of splicing factor(s) (34) . Of note, aberrant alternative splicing and overactivity of splicing factors has been recently reported in breast cancer (35) (36) (37) (38) . Additionally, aberrant splicing has been reported for ER mRNA in breast cancer (39, 40) . Given the aberrant splicing of TR␤2 mRNA in the TSHoma, it is possible that other mRNAs may be aberrantly spliced in the tumor and perhaps contribute to the growth of the tumor. Recently, an incidental pituitary adenoma in a patient with RTH was reported (41) . In addition, there is one case report of pituitary enlargement in a patient with RTH in whom pituitary regression occurred after thyroid hormone treatment (42) . However, TR␤ knockout mice and transgenic mice overexpressing mutant TR␤ showed defective TSH regulation but no increase in tendency to form TSHomas (11, 21, 22, 43) . Additionally, there have been no reported cases of TSHomas in RTH patients who have TR␤ mutations (12, 14) , and patients with RTH do not seem to have a higher risk for TSHomas. Mutant TR␤s per se may not be sufficient for the abnormal growth characteristics of TSHomas. Hence, the defective TR␤ splicing could be a consequence rather than a cause of tumorigenesis.
Several families with RTH have been described who do not have mutations in their TR␣ and TR␤ genes (44) . Although knockout mice that lack a coactivator have mild central thyroid hormone resistance (45) , no such postreceptor defects have been detected in these patients. Thus, it is possible that aberrantly spliced TRs may account for thyroid hormone resistance in some of these families. Hormone resistance in humans has been described for estrogen, glucocorticoid, androgen, and vitamin D, as well as peptide hormones, such as insulin, vasopressin, and PTH (46) (47) (48) (49) (50) (51) (52) . In many cases, mutations in the nuclear hormone receptors or peptide hormone receptors were detected in genomic DNA and accounted for the clinical picture of hormone resistance. However, in rare instances in which no receptor mutation was found, receptor down-regulation or postreceptor defects have been described or hypothesized (44, 51, 53, 54) . Our findings suggest that aberrant alternative splicing is another mechanism for hormone resistance in signaling pathways in which no receptor mutation is found in the genomic DNA.
In conclusion, we describe a splicing variant of TR from a TSH-secreting pituitary tumor that caused defective T 3 -dependent negative regulation of glycoprotein hormone ␣-subunit and TSH␤ genes in a transient transfection system. Since the TR␤ gene did not contain any mutations that accounted for the deletion, this abnormal TR was caused by aberrant alternative splicing of TR␤2 mRNA. This example enlarges our understanding of the possible mechanisms for hormone resistance and suggests that posttranscriptional causes need to be considered whenever genomic mutations are not detected in hormone receptors. 
MATERIALS AND METHODS
Analyses of RNA and Genomic DNA
Genomic DNA was isolated from the patient's TSHoma and peripheral blood leukocytes. Total RNA was extracted from the TSHoma by Trizol reagent (Life Technologies, Inc., Gaithersburg, MD). Pituitary gland polyA RNA (pool of 87 normal tissue specimens) was purchased from CLONTECH Laboratories, Inc. (Palo Alto, CA). cDNA was synthesized by Moloney murine leukemia virus-reverse transcriptase. DNA was amplified by PCR with the following specific oligonucleotide primers: TR␤1 sense primer: 5Ј-GGATCCAGAATGATTAC-TAACCTATGACTC-3Ј; TR␤2 sense primer: 5Ј-ACCAGG-GAAACAAAATGAACTACTGTATGC-3Ј; TR␤1 and TR␤2 common antisense primer: 5Ј-GGAATTATAGGAAGGAA-TCCAGTCAGTCTA-3Ј; TR␤2 exon 6 sense primer (corresponding to exon 9 of TR␤1): 5Ј-CTGCCATGTGAAGAC-CAGATCATCCT-3Ј; TR␤2 exon 6 antisense primer: 5Ј-CTGAAGACATCAGCAGGACGGCCTGA-3Ј; Sense primer sequence for TR␤2 exon 6 and flanking introns: 5Ј-TCACA-GAAGGTTATTCCTATT-3Ј; antisense primer sequence for TR␤2 exon 6 and flanking introns: 5Ј-ACTCAAGTGATTG-GAATTAG-3Ј; GAPDH sense primer: 5Ј-CATCACGCCACA-GTTTCCCGGAGG-3Ј; GAPDH antisense primer: 5Ј-TTTCTA-GACGGCAGGTCAGGTCCACC-3Ј. For semiquantitative RT-PCR, PCR conditions for temperature were optimized for each primer pair, and comparative kinetic analyses were performed to determine that the selected PCR cycle number for each primer pair was within the exponential phase of product generation. PCR products were visualized on 1% Tris-borate-EDTA agarose gels stained with ethidium bromide. Ethidium bromide-stained gels were digitized, and densitometry was performed on the product bands using Image Quant (Molecular Dynamics, Inc., Sunnyvale, CA) (55, 56) . Quantification of RT-PCR by analysis of ethidium-stained gels yielded consistent results. PCR products were subcloned into pCR4TOPO plasmid (Invitrogen, Carlsbad, CA), and then sequenced.
ss Profile Analysis
ss Profiles were analyzed by Michael Zhang's Exon Finder, a software program designed to predict ss sequences (19) .
Construction of TR cDNA Expression Vectors
The full-length human wild-type TR␤2 cDNA was cloned into pcDNA. The DNA fragment carrying the deletion mutation identified in the patient's TSHoma was digested with Tth111I and BglII and then subcloned into the corresponding TR␤2 region. A natural mutant TR␤1G345R from a patient with RTH was also digested with Tth111I and BglII and replaced with the corresponding TR␤2 region to create TR␤2G360R (TR␤2Mf). The final constructs were verified by sequencing.
T 3 Binding Assay
T 3 binding affinity of wild-type TR␤2 and TR␤2spl protein was measured in transfected CV-1 cells as described previously (57) . CV-1 cells were transiently transfected with wild-type TR␤2, TR␤2spl, or TR␤2Mf using Lipofectamine Plus (Life Technologies, Inc.). Cells were homogenized in 0.25 M sucrose and 3 mM MgCl 2 (SM). The crude nuclear pellet was suspended once with and once without 0.5% Triton X-100 in SM. Nuclear proteins were extracted by stirring isolated nuclei at 4 C for 1 h in 0.4 M KCl, 5 mM MgCl 2 , 1 mM dithiothreitol, and 0.05 M Tris-glycine HCl (pH 8.5). After nuclear extracts were centrifuged at 117,000 ϫ g for 45 min, T 3 -binding activities in the supernatants were assayed. Nuclear proteins (125 g) were incubated with 1 nM 125 I-T 3 (NEN Life Science Products, Boston, MA) and 4 nM non-labeled T 3 at 4 C overnight.
125 I-T 3 was separated from the bound form using AG1-X8 resin (Bio-Rad Laboratories, Inc., Richmond, CA). Nonspecific binding was determined in the incubation mixture containing a 10,000-fold amount of nonlabeled T 3 .
Cotransfection Studies of TR
TSA 201 cells (a strain of HEK293 cells transformed with T antigen) were maintained in Opti-MEM (Life Technologies, Inc.) containing 4% FCS pretreated with AG1-X8 resin to remove endogenous thyroid hormones. The cells were plated in six-well dishes and transfected 24 h later by the calcium phosphate precipitation method with 250 ng of TR expression vector and 500 ng of human glycoprotein hormone ␣-subunit promoter (Ϫ846 to ϩ44) linked to pA3 luciferase reporter gene (6) . Additionally, TSA201 cells were transfected with 400 ng of TR expression vector, 200 ng of human TSH␤ promoter (Ϫ1,192 to ϩ37) gene linked to pA3 luciferase reporter gene (15) , and 200 ng of human thyrotroph embryonic factor expression vector (obtained by RT-PCR) with Lipofectamine Plus. Eight hours after transfection, the cells were washed and incubated for 40 h with Opti-MEM media containing 1% of resin-treated FCS with and without 50 nM T 3 . The cells were lysed and assayed for luciferase activity. Luciferase activity was normalized according to protein concentration.
Yeast Two-Hybrid System
EGY48 yeast cells, p8op-lacZ, and LexA-parental vectors (pGilda) and B42-parental vectors (pB42AD) were purchased were subcloned into pB42AD to make B42AD-SRC-1, B42AD-TIF2, B42AD-NCoR, and B42AD-SMRT. LexA fusion vectors, B42AD fusion vectors, and p8op-lacZ were transformed into EGY48 according to the manufacturer's manual.
Interactions of fusion proteins were tested using selection for leucine auxotrophy and Lac Z reporter gene on plates in the presence and absence of 1 M T 3 .
